Do analysts recommend THCX or CPH?

Cipher Pharmaceuticals has a consensus price target of C$17.00, suggesting a potential upside of 18.88%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, THCX or CPH?

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hydropothecary N/A N/A N/A N/A N/A Cipher Pharmaceuticals C$49.62M 7.32 C$11.41M C$1.12 12.77

Cipher Pharmaceuticals (CPH) Competitors

C$14.30 +0.10 (+0.70%)

As of 09/11/2026 03:59 PM Eastern

Compare

CPH vs. DB, DHT.UN, GUD, THCX, and TLRY

Should you buy Cipher Pharmaceuticals stock or one of its competitors? Cipher Pharmaceuticals's main competitors and comparable companies include Decibel Cannabis (DB), DRI Healthcare Trust (DHT.UN), Knight Therapeutics (GUD), Hydropothecary (THCX), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cipher Pharmaceuticals compare to Decibel Cannabis?

Cipher Pharmaceuticals (TSE:CPH) and Decibel Cannabis (CVE:DB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Decibel Cannabis. Decibel Cannabis is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	7.32	C$11.41M	C$1.12	12.77
Decibel Cannabis	C$127.08M	0.49	-C$1.03M	-C$0.15	N/A

Cipher Pharmaceuticals has a net margin of 58.81% compared to Decibel Cannabis' net margin of -3.78%. Cipher Pharmaceuticals' return on equity of 22.74% beat Decibel Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Decibel Cannabis	-3.78%	-1.05%	3.04%

Cipher Pharmaceuticals has a beta of 1.045899, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Decibel Cannabis has a beta of 0.321627, meaning that its stock price is 68% less volatile than the broader market.

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Decibel Cannabis'average media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Decibel Cannabis	Neutral

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, indicating a potential upside of 18.88%. Decibel Cannabis has a consensus price target of C$0.18, indicating a potential downside of 89.13%. Given Cipher Pharmaceuticals' higher possible upside, research analysts plainly believe Cipher Pharmaceuticals is more favorable than Decibel Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decibel Cannabis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Decibel Cannabis shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Comparatively, 1.1% of Decibel Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats Decibel Cannabis on 11 of the 15 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Cipher Pharmaceuticals (TSE:CPH) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 0.8% of DRI Healthcare Trust shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, suggesting a potential upside of 18.88%. DRI Healthcare Trust has a consensus price target of C$25.20, suggesting a potential upside of 48.67%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts plainly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Cipher Pharmaceuticals has higher earnings, but lower revenue than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$49.62M	7.32	C$11.41M	C$1.12	12.77
DRI Healthcare Trust	C$172.34M	5.41	C$9.73M	-C$0.80	N/A

Cipher Pharmaceuticals has a beta of 1.045899, indicating that its share price is 5% more volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.365327, indicating that its share price is 63% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 22.74% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
DRI Healthcare Trust	5.02%	2.06%	4.22%

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled DRI Healthcare Trust'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
DRI Healthcare Trust	Neutral

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 10 of the 15 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Knight Therapeutics has a beta of -0.290935, meaning that its share price is 129% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.045899, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cipher Pharmaceuticals	Neutral

Cipher Pharmaceuticals has a net margin of 58.81% compared to Knight Therapeutics' net margin of 2.72%. Cipher Pharmaceuticals' return on equity of 22.74% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	2.72%	1.91%	0.51%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

22.3% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has lower revenue, but higher earnings than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$547.31M	1.77	-C$30.73M	C$0.15	65.67
Cipher Pharmaceuticals	C$49.62M	7.32	C$11.41M	C$1.12	12.77

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential downside of 3.55%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 18.88%. Given Cipher Pharmaceuticals' higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 22.74% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a consensus price target of C$17.00, suggesting a potential upside of 18.88%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Hydropothecary's average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hydropothecary	Neutral
Cipher Pharmaceuticals	Neutral

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	C$49.62M	7.32	C$11.41M	C$1.12	12.77

Summary

Cipher Pharmaceuticals beats Hydropothecary on 8 of the 8 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Tilray Brands currently has a consensus target price of C$13.30, suggesting a potential upside of 139.21%. Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 18.88%. Given Tilray Brands' higher probable upside, research analysts clearly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has a net margin of 58.81% compared to Tilray Brands' net margin of -15.22%. Cipher Pharmaceuticals' return on equity of 22.74% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-15.22%	-8.85%	-1.41%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

4.7% of Tilray Brands shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$915.45M	0.84	-C$183.24M	-C$1.09	N/A
Cipher Pharmaceuticals	C$49.62M	7.32	C$11.41M	C$1.12	12.77

In the previous week, Tilray Brands had 2 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 2 mentions for Tilray Brands and 0 mentions for Cipher Pharmaceuticals. Tilray Brands' average media sentiment score of 0.51 beat Cipher Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Positive
Cipher Pharmaceuticals	Neutral

Tilray Brands has a beta of 3.215277, suggesting that its stock price is 222% more volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.045899, suggesting that its stock price is 5% more volatile than the broader market.

Summary

Cipher Pharmaceuticals beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$360.89M	C$12.46B	C$7.14B	C$12.66B
Dividend Yield	N/A	2.62%	2.56%	6.28%
P/E Ratio	12.77	799.75	275.24	40.11
Price / Sales	7.32	763.36	656.02	9.50
Price / Cash	3.53	89.25	77.04	82.29
Price / Book	2.65	10.39	10.33	4.67
Net Income	C$11.41M	C$2.85B	C$3.50B	C$299.09M
7 Day Performance	-0.28%	-3.61%	-3.32%	-1.33%
1 Month Performance	1.35%	0.86%	-0.41%	-1.18%
1 Year Performance	-12.80%	3.47%	19.21%	23.80%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	N/A	C$14.30 +0.7%	C$17.00 +18.9%	-11.8%	C$360.89M	C$49.62M	12.77	5
DB Decibel Cannabis	0.6448 of 5 stars	C$1.81 -2.2%	C$0.18 -90.3%	+1,138.5%	C$1.04B	C$127.08M	N/A	83,000
DHT.UN DRI Healthcare Trust	N/A	C$17.46 -1.1%	C$25.20 +44.3%	+15.9%	C$960.17M	C$172.34M	N/A	N/A	Positive News
GUD Knight Therapeutics	N/A	C$10.04 +3.8%	C$9.50 -5.4%	+53.2%	C$949.90M	C$547.31M	66.93	725	High Trading Volume
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. DB, DHT.UN, GUD, THCX, and TLRY

How does Cipher Pharmaceuticals compare to Decibel Cannabis?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. DB, DHT.UN, GUD, THCX, and TLRY

How does Cipher Pharmaceuticals compare to Decibel Cannabis?

Which has higher earnings & valuation, CPH or DB?

Is CPH or DB more profitable?

Which has more risk and volatility, CPH or DB?

Does the media favor CPH or DB?

Do analysts prefer CPH or DB?

Do insiders & institutionals believe in CPH or DB?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Do institutionals & insiders hold more shares of CPH or DHT.UN?

Do analysts rate CPH or DHT.UN?

Which has preferable valuation & earnings, CPH or DHT.UN?

Which has more risk and volatility, CPH or DHT.UN?

Is CPH or DHT.UN more profitable?

Does the media prefer CPH or DHT.UN?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Which has more volatility & risk, GUD or CPH?

Does the media refer more to GUD or CPH?

Is GUD or CPH more profitable?

Do insiders and institutionals have more ownership in GUD or CPH?

Which has stronger valuation and earnings, GUD or CPH?

Do analysts recommend GUD or CPH?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Is THCX or CPH more profitable?

Do institutionals and insiders hold more shares of THCX or CPH?

Do analysts recommend THCX or CPH?

Does the media prefer THCX or CPH?

Which has stronger earnings & valuation, THCX or CPH?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Do analysts rate TLRY or CPH?

Is TLRY or CPH more profitable?

Do institutionals and insiders hold more shares of TLRY or CPH?

Which has preferable earnings & valuation, TLRY or CPH?

Does the media favor TLRY or CPH?

Which has more risk and volatility, TLRY or CPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools